NYSE:BSX - Boston Scientific Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$37.82 +0.33 (+0.88 %)
(As of 09/20/2018 04:00 PM ET)
Previous Close$37.49
Today's Range$37.55 - $37.92
52-Week Range$24.54 - $37.92
Volume4.68 million shs
Average Volume7.56 million shs
Market Capitalization$52.03 billion
P/E Ratio29.86
Dividend YieldN/A
Boston Scientific logoBoston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: Cardiovascular, Rhythm Management, and MedSurg. The company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions therapy products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as certain peripheral vessels; and structural heart therapy systems. It also provides stents, balloon catheters, wires, and atherectomy systems to treat arterial diseases; thrombectomy systems, wires, and stents to treat venous diseases; and peripheral embolization devices, microcatheters, and drainage catheters to treat various cancers. In addition, the company offers cardiac rhythm management devices, such as implantable cardioverter defibrillator systems to treat abnormalities; remote patient management system; implantable cardiac resynchronization therapy pacemaker systems; and medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising ablation catheters, intracardiac ultrasound catheters, diagnostic catheters, delivery sheaths, mapping system, and other accessories. Further, it provides products to diagnose and treat diseases of the gastrointestinal and pulmonary conditions; devices to diagnose, treat, and palliate pulmonary diseases within the airway and lungs; and products to treat various urological and pelvic conditions; deep brain stimulation systems for the treatment of parkinson's disease, tremor, and intractable primary and secondary dystonia; and spinal cord stimulator systems for the management of chronic pain. The company was founded in 1979 and is headquartered in Marlborough, Massachusetts.

Receive BSX News and Ratings via Email

Sign-up to receive the latest news and ratings for BSX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NYSE
Industry Surgical & medical instruments
Sub-IndustryHealth Care Equipment


Debt-to-Equity Ratio0.62
Current Ratio0.83
Quick Ratio0.60


Trailing P/E Ratio29.86
Forward P/E Ratio27.21
P/E Growth2.62

Sales & Book Value

Annual Sales$9.05 billion
Price / Sales5.78
Cash Flow$1.9043 per share
Price / Cash19.86
Book Value$5.11 per share
Price / Book7.40


EPS (Most Recent Fiscal Year)$1.26
Net Income$105 million
Net Margins5.48%
Return on Equity26.35%
Return on Assets10.12%


Outstanding Shares1,382,930,000
Market Cap$52.03 billion

Boston Scientific (NYSE:BSX) Frequently Asked Questions

What is Boston Scientific's stock symbol?

Boston Scientific trades on the New York Stock Exchange (NYSE) under the ticker symbol "BSX."

How were Boston Scientific's earnings last quarter?

Boston Scientific Co. (NYSE:BSX) announced its quarterly earnings results on Wednesday, July, 25th. The medical equipment provider reported $0.41 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.34 by $0.07. The medical equipment provider had revenue of $2.49 billion for the quarter, compared to the consensus estimate of $2.47 billion. Boston Scientific had a net margin of 5.48% and a return on equity of 26.35%. Boston Scientific's revenue for the quarter was up 10.3% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.32 EPS. View Boston Scientific's Earnings History.

When is Boston Scientific's next earnings date?

Boston Scientific is scheduled to release their next quarterly earnings announcement on Thursday, October, 25th 2018. View Earnings Estimates for Boston Scientific.

What guidance has Boston Scientific issued on next quarter's earnings?

Boston Scientific updated its FY18 earnings guidance on Wednesday, July, 25th. The company provided EPS guidance of $1.37-1.41 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $1.39. The company issued revenue guidance of +8-9% to $9.80-9.88 billion, compared to the consensus revenue estimate of $9.82 billion.Boston Scientific also updated its Q3 guidance to $0.33-0.35 EPS.

What price target have analysts set for BSX?

23 Wall Street analysts have issued twelve-month price objectives for Boston Scientific's stock. Their forecasts range from $27.00 to $43.00. On average, they anticipate Boston Scientific's share price to reach $36.5455 in the next year. This suggests that the stock has a possible downside of 3.4%. View Analyst Price Targets for Boston Scientific.

What is the consensus analysts' recommendation for Boston Scientific?

23 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Boston Scientific in the last year. There are currently 2 hold ratings, 18 buy ratings and 3 strong buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Boston Scientific.

What are Wall Street analysts saying about Boston Scientific stock?

Here are some recent quotes from research analysts about Boston Scientific stock:
  • 1. Needham & Company LLC analysts commented, "BSX announced it is acquiring the private company Augmenix for $500M cash up front and up to $100M in milestones. Augmenix’s SpaceOAR reduces side effects associated with prostate radiotherapy. BSX expects the deal to be immaterial to its adjusted EPS through 2019 and increasingly accretive beginning in 2020. The SpaceOAR hydrogel is CE Marked and FDA cleared and serves an estimated $750M market. We expect the deal to strengthen BSX’s Urology & Pelvic Health business. We expect BSX’s string of acquisitions in 2018 (including Augmenix) to combine to provide a material benefit to its longer-term organic growth and we reiterate our Strong Buy rating and raise our price target to $43 from $39." (9/7/2018)
  • 2. According to Zacks Investment Research, "Boston Scientific's delay in the relaunch of the Lotus range of heart devices is expected to hamper sales in 2018 too. We are also concerned about the declining worldwide pacemaker sales hurting Boston Scientific’s CRM business. A competitive market also adds to the woes. However, the company has been gaining from impressive growth across all its business lines and geographies. The 2018 view also paints a bright picture for the near term. Boston Scientific achieved clinical milestones for Ranger Drug Coated Balloon and WATCHMAN Left Atrial Appendage Closure device. Also, post the suspension of Lotus valve in Europe, ACURATE TAVR valve platform continues to build momentum. Lately, the company announced several strategic acquisitions including NxThera and nVision in Urology and Pelvic Health, EmCision in Endoscopy, Securus in EP and Millipede in Structural Heart. Overall, Boston Scientific outperformed its industry in a year’s time." (7/17/2018)
  • 3. Canaccord Genuity analysts commented, "We reiterate our BUY rating and $35 year-end target price on shares of BSX. Our key takeaways from our meeting last week with senior management in San Francisco (as well as incremental tidbits we gleaned over the weekend at the North American Neuromodulation Society (NANS) conference in Vegas) support our general hypothesis on the stock: We expect BSX to deliver top- and bottom-line growth rates above the large-cap medical device peer group average over the 2018-2020 timeframe." (1/17/2018)

Who are some of Boston Scientific's key competitors?

Who are Boston Scientific's key executives?

Boston Scientific's management team includes the folowing people:
  • Mr. Michael F. Mahoney, Chairman, Pres & CEO (Age 53)
  • Mr. Daniel J. Brennan, Exec. VP & CFO (Age 52)
  • Mr. Joseph M. Fitzgerald, Exec. VP & Pres of Rhythm Management (Age 54)
  • Mr. Kevin J. Ballinger, Exec. VP & Pres of Interventional Cardiology (Age 45)
  • Mr. Edward F. Mackey, Exec. VP of Operations (Age 55)

Has Boston Scientific been receiving favorable news coverage?

News articles about BSX stock have been trending somewhat positive this week, Accern Sentiment reports. Accern rates the sentiment of media coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Boston Scientific earned a news impact score of 0.18 on Accern's scale. They also assigned press coverage about the medical equipment provider an impact score of 46.57 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company's share price in the next few days. View Recent Headlines for Boston Scientific.

Who are Boston Scientific's major shareholders?

Boston Scientific's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include FMR LLC (11.33%), BlackRock Inc. (7.91%), Janus Henderson Group PLC (3.02%), Bollard Group LLC (2.42%), Artisan Partners Limited Partnership (1.83%) and Bank of New York Mellon Corp (1.31%). Company insiders that own Boston Scientific stock include Arthur C Butcher, Daniel J Brennan, David A Pierce, Eric Francis Yves Thepaut, Jeffrey B Mirviss, John Bradley Sorenson, John E Sununu, Joseph Michael Fitzgerald, Keith D Dawkins, Kevin J Ballinger, Maulik Nanavaty, Michael F Mahoney, Michael P Phalen, Supratim Bose, Timothy A Pratt, Valley Gold Master Fund L Sun and Wendy Carruthers. View Institutional Ownership Trends for Boston Scientific.

Which institutional investors are selling Boston Scientific stock?

BSX stock was sold by a variety of institutional investors in the last quarter, including Boston Partners, Artisan Partners Limited Partnership, Voya Investment Management LLC, Bank of Montreal Can, Wells Fargo & Company MN, Bank of New York Mellon Corp, Bank of New York Mellon Corp and Orbimed Advisors LLC. Company insiders that have sold Boston Scientific company stock in the last year include Arthur C Butcher, Daniel J Brennan, David A Pierce, Eric Francis Yves Thepaut, Jeffrey B Mirviss, John Bradley Sorenson, John E Sununu, Joseph Michael Fitzgerald, Kevin J Ballinger, Maulik Nanavaty, Michael F Mahoney, Michael P Phalen, Supratim Bose and Timothy A Pratt. View Insider Buying and Selling for Boston Scientific.

Which institutional investors are buying Boston Scientific stock?

BSX stock was purchased by a variety of institutional investors in the last quarter, including FMR LLC, Morgan Stanley, Epoch Investment Partners Inc., BlackRock Inc., TD Asset Management Inc., Marshall Wace LLP, Putnam Investments LLC and First Quadrant L P CA. Company insiders that have bought Boston Scientific stock in the last two years include John E Sununu and Valley Gold Master Fund L Sun. View Insider Buying and Selling for Boston Scientific.

How do I buy shares of Boston Scientific?

Shares of BSX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Boston Scientific's stock price today?

One share of BSX stock can currently be purchased for approximately $37.83.

How big of a company is Boston Scientific?

Boston Scientific has a market capitalization of $52.03 billion and generates $9.05 billion in revenue each year. The medical equipment provider earns $105 million in net income (profit) each year or $1.26 on an earnings per share basis. Boston Scientific employs 29,000 workers across the globe.

How can I contact Boston Scientific?

Boston Scientific's mailing address is 300 BOSTON SCIENTIFIC WAY, MARLBOROUGH MA, 01752. The medical equipment provider can be reached via phone at 508-683-4000 or via email at [email protected]

MarketBeat Community Rating for Boston Scientific (NYSE BSX)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  705 (Vote Outperform)
Underperform Votes:  603 (Vote Underperform)
Total Votes:  1,308
MarketBeat's community ratings are surveys of what our community members think about Boston Scientific and other stocks. Vote "Outperform" if you believe BSX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BSX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 9/20/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel